Work

Classic Psychedelics for the Treatment of Depressive Disorders: An Update for Psychiatrists in Training

Year: 2023

Type: article

Abstract: Psychedelics as therapeutic agents have generated significant attention from clinicians and media sources in recent years. The authors provide an update to the psychiatric trainee on the evidence for psychedelics in the treatment of major depressive disorder and treatment-resistant depression. Many modern clinical trials of the classic, serotonergic psychedelics, such as psilocybin, ayahuasca, lysergic acid diethylamide, and N,N-dimethyltryptamine, have shown promise in the treatment of depressive disorders. Future clinical trials should elucidate severe adverse effects and explore the efficacy of psychedelics utilizing larger, double-blinded trials.

Source: American Journal of Psychiatry Residents Journal

DOI: 10.1176/appi.ajp-rj.2023.190103

Authors: Lawrence Canale, Dhvanit Raval, Preet Chatha, Katie Penn, C. Gabrie Weber, Catherine Stout, Jeremy Weleff

Institutions: Cleveland Clinic, Kansas City University, Yale University

Language: English

Topic: Psychedelics and Drug Studies

Subfield: Clinical Psychology

Field: Psychology

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4386544759

FWCI:

Cites: 19

Cited by:

Related to: 10